Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOV bicifadine NDA in first half of 2007

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

DOV will perform a human QT study for its non-opioid analgesic prior to its planned NDA submission in the first half of 2007, the firm says Feb 12. The company is conducting the study "as it appears this is an emerging standard for all new molecular entities," and not due to safety issues with the agent. "To date, there have been no electrocardiogram - or other - safety concerns in DOV's preclinical studies or in clinical studies involving more than 2,500 subjects treated with bicifadine," DOV maintains. The initial bicifadine NDA will support use in chronic low back pain. DOV recently discontinued development of its GABA receptor antagonist ocinaplon for generalized anxiety disorder (1Pharmaceutical Approvals Monthly November 2005, In Brief); other projects include triple-uptake inhibitors, in development with partner Merck for depression...

You may also be interested in...



DOV drops ocinaplon

DOV is discontinuing development of its GABA receptor agonist ocinaplon "due to an unacceptable rate of liver enzyme elevations," the firm says Oct. 28. Ocinaplon, which had been in development for generalized anxiety disorder, had experienced several clinical holds, the most recent occurring in August (1Pharmaceutical Approvals Monthly September 2005, p. 15). "DOV will select a follow-on candidate from one of the backup compounds in its preclinical program," the company says. The firm also confirmed plans to submit an NDA for use of its non-opioid analgesic bicifadine in chronic low back pain during the first half of 2007. Phase II studies in osteoarthritis and neuropathic pain are slated to begin in the fourth quarter of 2005; an acute pain sNDA is slated for the fourth quarter of 2007...

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by 

Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits

California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel